{"title":"Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects.","authors":"Bayazid Ghaderi, Sabrieh Amini, Farzad Maroofi, Chiya Jalali, Mitra Javanmardi, Daem Roshani, Mohammad Abdi","doi":"10.17795/ijcp-5069","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>B cell chronic lymphocytic leukemia is one of the most frequent hematologic malignancies in the world. Cellular surface CD markers and serum Beta-2-microglobulin may be used as a prognostic tool in CLL patients.</p><p><strong>Objectives: </strong>In the present study we introduce serum adenosine deaminase as a diagnostic marker in CLL.</p><p><strong>Materials and methods: </strong>Blood samples were collected from B-CLL and healthy subjects. White blood cell, red blood cell and platelet count and blood Erythrocyte sedimentation rate was recorded and serum Beta-2-microglobulin, Lactate dehydrogenase and total ADA enzyme activity were determined.</p><p><strong>Results: </strong>Serum ADA activity was significantly higher in patients group than that of controls. ADA had a significant and direct correlation with B2M, WBC, LDH and ESR. However, there was not any relation between ADA and the stages of disease. Diagnostic cut-off, sensitivity and specificity of the serum ADA test were 27.97 U/L, 91% and 94%, respectively.</p><p><strong>Conclusions: </strong>A higher ADA activity in patients group and its correlation with CLL markers were seen in our study. High diagnostic value of serum ADA in our study suggests that it might be considered as a useful screening tool among the other markers in CLL.</p>","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":"9 1","pages":"e5069"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038830/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of cancer prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17795/ijcp-5069","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: B cell chronic lymphocytic leukemia is one of the most frequent hematologic malignancies in the world. Cellular surface CD markers and serum Beta-2-microglobulin may be used as a prognostic tool in CLL patients.
Objectives: In the present study we introduce serum adenosine deaminase as a diagnostic marker in CLL.
Materials and methods: Blood samples were collected from B-CLL and healthy subjects. White blood cell, red blood cell and platelet count and blood Erythrocyte sedimentation rate was recorded and serum Beta-2-microglobulin, Lactate dehydrogenase and total ADA enzyme activity were determined.
Results: Serum ADA activity was significantly higher in patients group than that of controls. ADA had a significant and direct correlation with B2M, WBC, LDH and ESR. However, there was not any relation between ADA and the stages of disease. Diagnostic cut-off, sensitivity and specificity of the serum ADA test were 27.97 U/L, 91% and 94%, respectively.
Conclusions: A higher ADA activity in patients group and its correlation with CLL markers were seen in our study. High diagnostic value of serum ADA in our study suggests that it might be considered as a useful screening tool among the other markers in CLL.
背景：B细胞慢性淋巴细胞白血病是世界上最常见的血液系统恶性肿瘤之一。细胞表面CD标记物和血清β-2-微球蛋白可作为CLL患者的预后工具：在本研究中，我们将血清腺苷脱氨酶作为 CLL 的诊断指标：采集B-CLL和健康受试者的血样。记录白细胞、红细胞、血小板计数和红细胞沉降率，测定血清β-2-微球蛋白、乳酸脱氢酶和总 ADA 酶活性：结果：患者组的血清 ADA 活性明显高于对照组。ADA 与 B2M、WBC、LDH 和 ESR 有明显的直接相关性。但 ADA 与疾病的分期没有任何关系。血清 ADA 检测的诊断临界值、敏感性和特异性分别为 27.97 U/L、91% 和 94%：我们的研究发现，患者组的 ADA 活性较高，且与 CLL 标志物相关。在我们的研究中，血清 ADA 具有很高的诊断价值，这表明它可被视为 CLL 其他标志物中的一种有用的筛查工具。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
